<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015807</url>
  </required_header>
  <id_info>
    <org_study_id>36707</org_study_id>
    <nct_id>NCT01015807</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane (TAP) Block for Cesarean Section</brief_title>
  <acronym>CLOTAP</acronym>
  <official_title>Transversus Abdominis Plane (TAP) Block for Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a transversus abdominis plane (TAP) block
      with Clonidine added to the injectate (Clo-TAP) performed approximately 2hrs after the
      cesarean section (CS) will decrease the amount of postoperative hyperalgesia and ultimately
      reduce post-CS chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute severe pain after cesarean section (CS) occurs more often than is thought and 10-15% of
      the women having a cesarean section develop chronic pain (Kehlet et al. 2006). With over 1.3
      million cesarean deliveries per year in the US, this is bound to create a significant health
      problem. One way to address this health burden is to refine techniques that may help control
      the pain women experience after CS and ultimately reduce the potential to develop chronic
      pain.

      The purpose of this randomized, double-blinded study is to evaluate the ability of an
      established anesthetic technique called the transversus abdominis plane (TAP) block to reduce
      the amount of hyperalgesia women develop around their incision after CS. Measuring the amount
      of punctuate mechanical hyperalgesia is used as a tool to assess postoperative central
      sensitization (Lavand'homme et al. 2005), which contributes to postoperative acute pain.
      Since postoperative acute pain has been shown to be predictive of developing postoperative
      chronic pain (Eisenach et al. 2008; Yarnitsky et al. 2008), an effective TAP block could help
      diminish the incidence of chronic pain after CS. In addition, blood samples will be collected
      for future genetic analysis and we will test preoperatively for mechanical temporal summation
      (mTS) to evaluate CNS (central nervous system) sensitization and nociceptive system
      hyperexcitability and see if this correlates with the amount of hyperalgesia women develop
      around their incision after surgery.

      The primary aim of this study is to evaluate the benefits of two different solutions injected
      by TAP block technique on postoperative peri-incisional hyperalgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Hyperalgesia Index (WHA) Assessed 48 Hrs After Block Placement in the Different Groups</measure>
    <time_frame>48hrs after CS</time_frame>
    <description>Determine which of three different TAP formulations (Placebo, TAP, Clo-TAP) has the most beneficial effect on the postoperative area of hyperalgesia 48hrs after the start of the cesarean section. The smaller the area of WHA, assessed in cm2, the better the outcome. Area sizes may range from 0 to any size.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hyperalgesia, Secondary</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP (Bupi)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clo-TAP (Bupi + Clon)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Placebo</intervention_name>
    <description>2 x 20mL 0.9% NaCl</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Bupi Placebo</other_name>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine Placebo</intervention_name>
    <description>2 x 1mL 0.9% NaCl</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAP (Bupi)</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine</description>
    <arm_group_label>TAP (Bupi)</arm_group_label>
    <arm_group_label>Clo-TAP (Bupi + Clon)</arm_group_label>
    <other_name>Bupivacaine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>2 x 1ml Clonidine = 150 µg Clonidine</description>
    <arm_group_label>Clo-TAP (Bupi + Clon)</arm_group_label>
    <other_name>Clonidine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-laboring women who will benefit from and have clinically consented to a scheduled
             or non-scheduled cesarean delivery under spinal anesthesia

          -  English speaking (UW Site) or Portuguese speaking (Brazil site)

          -  aged between 18 and 45 years

          -  BMI &lt; 40

          -  ASA physical status class I or II

        Exclusion Criteria:

          -  laboring women undergoing a non-scheduled cesarean delivery

          -  non-English speaking (UW Site) or non-Portuguese speaking (Brazil site)

          -  previous spinal surgery

          -  contraindications for neuraxial anesthesia

          -  allergy to local anesthetic, ultrasound conduction gel, or Clonidine

          -  history of chronic pain

          -  inability to receive intraoperative Toradol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Landau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Bollag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Santa Joana</name>
      <address>
        <city>São Paulo</city>
        <zip>04103-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buchanan ML, Easterling TR, Carr DB, Shen DD, Risler LJ, Nelson WL, Mattison DR, Hebert MF. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos. 2009 Apr;37(4):702-5. doi: 10.1124/dmd.108.024984. Epub 2008 Dec 30.</citation>
    <PMID>19116263</PMID>
  </reference>
  <reference>
    <citation>Carvalho B, Angst MS, Fuller AJ, Lin E, Mathusamy AD, Riley ET. Experimental heat pain for detecting pregnancy-induced analgesia in humans. Anesth Analg. 2006 Nov;103(5):1283-7.</citation>
    <PMID>17056970</PMID>
  </reference>
  <reference>
    <citation>Duma A, Urbanek B, Sitzwohl C, Kreiger A, Zimpfer M, Kapral S. Clonidine as an adjuvant to local anaesthetic axillary brachial plexus block: a randomized, controlled study. Br J Anaesth. 2005 Jan;94(1):112-6. Epub 2004 Oct 29.</citation>
    <PMID>15516351</PMID>
  </reference>
  <reference>
    <citation>Eisenach JC, De Kock M, Klimscha W. alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology. 1996 Sep;85(3):655-74. Review.</citation>
    <PMID>8853097</PMID>
  </reference>
  <reference>
    <citation>Gabriel JS, Gordin V. Alpha 2 agonists in regional anesthesia and analgesia. Curr Opin Anaesthesiol. 2001 Dec;14(6):751-3.</citation>
    <PMID>17019175</PMID>
  </reference>
  <reference>
    <citation>Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review.</citation>
    <PMID>16698416</PMID>
  </reference>
  <reference>
    <citation>Landau R, Schiffer E, Morales M, Savoldelli G, Kern C. The dose-sparing effect of clonidine added to ropivacaine for labor epidural analgesia. Anesth Analg. 2002 Sep;95(3):728-34, table of contents.</citation>
    <PMID>12198061</PMID>
  </reference>
  <reference>
    <citation>Lavand'homme P. Postcesarean analgesia: effective strategies and association with chronic pain. Curr Opin Anaesthesiol. 2006 Jun;19(3):244-8. Review.</citation>
    <PMID>16735805</PMID>
  </reference>
  <reference>
    <citation>Lavand'homme P. Perioperative pain. Curr Opin Anaesthesiol. 2006 Oct;19(5):556-61. Review.</citation>
    <PMID>16960491</PMID>
  </reference>
  <reference>
    <citation>Lavand'homme P, De Kock M, Waterloos H. Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery. Anesthesiology. 2005 Oct;103(4):813-20.</citation>
    <PMID>16192774</PMID>
  </reference>
  <reference>
    <citation>Lavand'homme PM, Roelants F, Waterloos H, Collet V, De Kock MF. An evaluation of the postoperative antihyperalgesic and analgesic effects of intrathecal clonidine administered during elective cesarean delivery. Anesth Analg. 2008 Sep;107(3):948-55. doi: 10.1213/ane.0b013e31817f1595.</citation>
    <PMID>18713912</PMID>
  </reference>
  <reference>
    <citation>Lavand'homme PM, Roelants F, Waterloos H, De Kock MF. Postoperative analgesic effects of continuous wound infiltration with diclofenac after elective cesarean delivery. Anesthesiology. 2007 Jun;106(6):1220-5.</citation>
    <PMID>17525598</PMID>
  </reference>
  <reference>
    <citation>Marhofer P, Greher M, Kapral S. Ultrasound guidance in regional anaesthesia. Br J Anaesth. 2005 Jan;94(1):7-17. Epub 2004 Jul 26. Review.</citation>
    <PMID>15277302</PMID>
  </reference>
  <reference>
    <citation>McCartney CJ, Duggan E, Apatu E. Should we add clonidine to local anesthetic for peripheral nerve blockade? A qualitative systematic review of the literature. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):330-8. Review.</citation>
    <PMID>17720118</PMID>
  </reference>
  <reference>
    <citation>McDonnell JG, Curley G, Carney J, Benton A, Costello J, Maharaj CH, Laffey JG. The analgesic efficacy of transversus abdominis plane block after cesarean delivery: a randomized controlled trial. Anesth Analg. 2008 Jan;106(1):186-91, table of contents. doi: 10.1213/01.ane.0000290294.64090.f3.</citation>
    <PMID>18165577</PMID>
  </reference>
  <reference>
    <citation>McDonnell JG, Laffey JG. Transversus abdominis plane block. Anesth Analg. 2007 Sep;105(3):883.</citation>
    <PMID>17717264</PMID>
  </reference>
  <reference>
    <citation>McDonnell JG, O'Donnell BD, Farrell T, Gough N, Tuite D, Power C, Laffey JG. Transversus abdominis plane block: a cadaveric and radiological evaluation. Reg Anesth Pain Med. 2007 Sep-Oct;32(5):399-404.</citation>
    <PMID>17961838</PMID>
  </reference>
  <reference>
    <citation>Mendez R, Eisenach JC, Kashtan K. Epidural clonidine analgesia after cesarean section. Anesthesiology. 1990 Nov;73(5):848-52.</citation>
    <PMID>2240674</PMID>
  </reference>
  <reference>
    <citation>Nikolajsen L, Sørensen HC, Jensen TS, Kehlet H. Chronic pain following Caesarean section. Acta Anaesthesiol Scand. 2004 Jan;48(1):111-6.</citation>
    <PMID>14674981</PMID>
  </reference>
  <reference>
    <citation>Ohel I, Walfisch A, Shitenberg D, Sheiner E, Hallak M. A rise in pain threshold during labor: a prospective clinical trial. Pain. 2007 Nov;132 Suppl 1:S104-8. Epub 2007 Jun 20.</citation>
    <PMID>17583429</PMID>
  </reference>
  <reference>
    <citation>Pan PH, Coghill R, Houle TT, Seid MH, Lindel WM, Parker RL, Washburn SA, Harris L, Eisenach JC. Multifactorial preoperative predictors for postcesarean section pain and analgesic requirement. Anesthesiology. 2006 Mar;104(3):417-25.</citation>
    <PMID>16508387</PMID>
  </reference>
  <reference>
    <citation>Parker RK, Connelly NR, Lucas T, Serban S, Pristas R, Berman E, Gibson C. Epidural clonidine added to a bupivacaine infusion increases analgesic duration in labor without adverse maternal or fetal effects. J Anesth. 2007;21(2):142-7. Epub 2007 May 30.</citation>
    <PMID>17458641</PMID>
  </reference>
  <reference>
    <citation>Weissman-Fogel I, Granovsky Y, Crispel Y, Ben-Nun A, Best LA, Yarnitsky D, Granot M. Enhanced presurgical pain temporal summation response predicts post-thoracotomy pain intensity during the acute postoperative phase. J Pain. 2009 Jun;10(6):628-36. doi: 10.1016/j.jpain.2008.12.009. Epub 2009 Apr 23.</citation>
    <PMID>19398382</PMID>
  </reference>
  <reference>
    <citation>Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, Best LA, Granot M. Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. Pain. 2008 Aug 15;138(1):22-8. Epub 2008 Jan 8.</citation>
    <PMID>18079062</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <results_first_submitted>December 2, 2014</results_first_submitted>
  <results_first_submitted_qc>May 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Laurent Bollag</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Anesthesiology and Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>postoperative</keyword>
  <keyword>hyperalgesia</keyword>
  <keyword>pain</keyword>
  <keyword>transversus abdominis plane block</keyword>
  <keyword>TAP block</keyword>
  <keyword>cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
Bupivacaine Placebo: 2 x 20mL 0.9% NaCl
Clonidine Placebo: 2 x 1mL 0.9% NaCl</description>
        </group>
        <group group_id="P2">
          <title>TAP (Bupi)</title>
          <description>2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
Clonidine Placebo: 2 x 1mL 0.9% NaCl
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine</description>
        </group>
        <group group_id="P3">
          <title>Clo-TAP (Bupi + Clon)</title>
          <description>2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
Clonidine: 2 x 1ml Clonidine = 150 µg Clonidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
Bupivacaine Placebo: 2 x 20mL 0.9% NaCl
Clonidine Placebo: 2 x 1mL 0.9% NaCl</description>
        </group>
        <group group_id="B2">
          <title>TAP (Bupi)</title>
          <description>2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
Clonidine Placebo: 2 x 1mL 0.9% NaCl
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine</description>
        </group>
        <group group_id="B3">
          <title>Clo-TAP (Bupi + Clon)</title>
          <description>2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
Clonidine: 2 x 1ml Clonidine = 150 µg Clonidine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="6.7"/>
                    <measurement group_id="B2" value="31.8" spread="4.5"/>
                    <measurement group_id="B3" value="29.5" spread="6.7"/>
                    <measurement group_id="B4" value="30" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Hyperalgesia Index (WHA) Assessed 48 Hrs After Block Placement in the Different Groups</title>
        <description>Determine which of three different TAP formulations (Placebo, TAP, Clo-TAP) has the most beneficial effect on the postoperative area of hyperalgesia 48hrs after the start of the cesarean section. The smaller the area of WHA, assessed in cm2, the better the outcome. Area sizes may range from 0 to any size.</description>
        <time_frame>48hrs after CS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
Bupivacaine Placebo: 2 x 20mL 0.9% NaCl
Clonidine Placebo: 2 x 1mL 0.9% NaCl</description>
          </group>
          <group group_id="O2">
            <title>TAP (Bupi)</title>
            <description>2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
Clonidine Placebo: 2 x 1mL 0.9% NaCl
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Clo-TAP (Bupi + Clon)</title>
            <description>2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
Clonidine: 2 x 1ml Clonidine = 150 µg Clonidine</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Hyperalgesia Index (WHA) Assessed 48 Hrs After Block Placement in the Different Groups</title>
          <description>Determine which of three different TAP formulations (Placebo, TAP, Clo-TAP) has the most beneficial effect on the postoperative area of hyperalgesia 48hrs after the start of the cesarean section. The smaller the area of WHA, assessed in cm2, the better the outcome. Area sizes may range from 0 to any size.</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.48" upper_limit="3.26"/>
                    <measurement group_id="O2" value="1.27" lower_limit="0.59" upper_limit="2.95"/>
                    <measurement group_id="O3" value="0.74" lower_limit="0.09" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We estimated that 25 subjects per group would allow us to detect a reduction of this area from 7.5 cm2 in our placebo group to 3.5 cm2 in the CloTAP group, with SD = 5 cm2 in both groups, owing to improved overall analgesia and reduced pain sensitization in women allocated to receive a TAP block with clonidine (2-tailed [alpha] = 0.05, 80% power). To allow for failed TAP blocks and/or exclusions of cases, we included 30 patients per group (n = 90)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
Bupivacaine Placebo: 2 x 20mL 0.9% NaCl
Clonidine Placebo: 2 x 1mL 0.9% NaCl</description>
        </group>
        <group group_id="E2">
          <title>TAP (Bupi)</title>
          <description>2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
Clonidine Placebo: 2 x 1mL 0.9% NaCl
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine</description>
        </group>
        <group group_id="E3">
          <title>Clo-TAP (Bupi + Clon)</title>
          <description>2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
Bupivacaine: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
Clonidine: 2 x 1ml Clonidine = 150 µg Clonidine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="030"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>LAST</sub_title>
                <description>Local anesthetic systemic toxicity</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Laurent Bollag</name_or_title>
      <organization>Univerisity of Washington</organization>
      <phone>+12063277328</phone>
      <email>bollag@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

